Yearly Archives: 2019


Human Heart Cells Transform in Space; Return to Normal on Earth: Study – The Weather Channel

Representational image

Heart cells are altered in space, but return to normal within 10 days on Earth, say researchers who examined cell-level cardiac function and gene expression in human heart cells cultured aboard the International Space Station (ISS) for 5.5 weeks.

Exposure to microgravity altered the expression of thousands of genes, but largely normal patterns of gene expression reappeared within 10 days after returning to Earth, according to the study published in the journal Stem Cell Reports.

"We're surprised about how quickly human heart muscle cells are able to adapt to the environment in which they are placed, including microgravity," said senior study author Joseph C. Wu from Stanford University.

These studies may not only provide insight into cellular mechanisms that could benefit astronaut health during long-duration spaceflight, but also potentially lay the foundation for new insights into improving heart health on Earth.

Past studies have shown that spaceflight induces physiological changes in cardiac function, including reduced heart rate, lowered arterial pressure, and increased cardiac output.

But to date, most cardiovascular microgravity physiology studies have been conducted either in non-human models or at tissue, organ, or systemic levels.

Relatively little is known about the role of microgravity in influencing human cardiac function at the cellular level.

To address this question, the research team studied human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). They generated hiPSC lines from three individuals by reprogramming blood cells, and then differentiated them into heart cells.

Beating heart cells were then sent to the ISS aboard a SpaceX spacecraft as part of a commercial resupply service mission. Simultaneously, ground control heart cells were cultured on Earth for comparison purposes.

Upon return to Earth, space-flown heart cells showed normal structure and morphology. However, they did adapt by modifying their beating pattern and calcium recycling patterns.

In addition, the researchers performed RNA sequencing of heart cells harvested at 4.5 weeks aboard the ISS, and 10 days after returning to Earth.

These results showed that 2,635 genes were differentially expressed among flight, post-flight, and ground control samples.

Most notably, gene pathways related to mitochondrial function were expressed more in space-flown heart cells.

A comparison of the samples revealed that heart cells adopt a unique gene expression pattern during spaceflight, which reverts to one that is similar to ground-side controls upon return to normal gravity, the study noted.

According to Wu, limitations of the study include its short duration and the use of 2D cell culture.

In future studies, the researchers plan to examine the effects of spaceflight and microgravity using more physiologically relevant hiPSC-derived 3D heart tissues with various cell types, including blood vessel cells.

"We also plan to test different treatments on the human heart cells to determine if we can prevent some of the changes the heart cells undergo during spaceflight," Wu said.

Read this article:
Human Heart Cells Transform in Space; Return to Normal on Earth: Study - The Weather Channel

The Value and Versatility of Clinical Flow Cytometry – Technology Networks

What is flow cytometry and how does it work?Flow cytometry(FCM) is a scientific technique used to measure the physical and biochemical characteristics of cells.1The sample is injected into the flow cytometer instrument, where it is typically focused to flow one cell at a time past light sources and detectors. Tens of thousands of cells can be examined in seconds to determine their morphology, granularity, scattering and transmission of light, or fluorescence of biomarkers, depending on the variation of FCM used.

The first conventional fluorescence-based flow cytometer was developed and commercialized in the late 60s/early 70s in Germany.2 Over the last five decades, FCM has developed rapidly in terms of the number of its applications and the quantity and dimensionality of the data it generates.1,3 Dr. Minh Doan, formerly of the Imaging Platform of the Broad Institute (USA) and now head of Bioimaging Analytics at GlaxoSmithKline in the USA, states, There have been significant advances in all three Vs of flow cytometry data: velocity (throughput/speed of data acquisition), volume (data content), and variety (sample types and signal acquisition technology).

Michael Parsons, manager of the Flow Cytometry Core of the Lunenfeld-Tanenbaum Research Institute in Toronto, Canada, agrees. The two biggest trends in flow cytometry are high content data and the merging of technologies from separate disciplines. For example, the last five years or so have seen the emergence of mass cytometry, which merges the disciplines of flow cytometry and mass spectrometry. In its latest iteration, an image cytometry module has been incorporated to generate unprecedented amounts of content (number of measured parameters) from relatively small amounts of patient tissue. Spectral flow cytometry has also established itself as an important emerging technology. Indeed, mass cytometry can now measure up to 50 features on a single cell simultaneously using antibodies tagged with rare earth metals,4 and imaging flow cytometry allows for 1000s of morphological features and multiple fluorescence markers to be analyzed per cell.3Flow cytometry, therefore, has inarguable potential as a clinical tool for disease diagnosis, prognosis, and therapeutic monitoring. However, some challenges remain in translating the full promise of FCM into clinical practice. Here, some of the current clinical applications of FCM will be discussed, as well as some of the compelling new applications being researched.

Similarly, FCM of liquid biopsies could be used to detect circulating tumor cells in the bloodstream.3 These cells are extremely rare, and with its high sensitivity, FCM is perfectly poised to make a significant impact in this area. This approach has potential for the clinical detection of early-stage cancer as well as the detection of circulating metastatic or drug-resistant cancer cells. For example, a study published earlier this year described label-free liquid biopsy with very high throughput (> 1 million cells/second) for drug-susceptibility testing during leukemia treatment.8

Prior to an organ transplant, FCM can be used to crossmatch the patient's serum with donor lymphocytes to detect antibodies that could result in organ rejection.1 Postoperatively, the analysis of various cell markers on the peripheral blood lymphocytes can indicate early transplant rejection, detect bone marrow toxicity arising from immunosuppressive therapies, and help differentiate infections from organ rejection. For blood transfusions, FCM can be used to detect contamination of blood with residual white blood cells, which can have adverse effects such as pulmonary edema.9Groups such as Dr. Roshini Abrahams at Nationwide Childrens Hospital in Ohio, USA, are using FCM to diagnose primary immunodeficiency disorders with the use of immunophenotyping and functional assays.10 These disorders are caused by genetic mutations that result in defects in the immune system, such as X-linked (Brutons) agammaglobulinemia and X-linked hyper-IgM syndrome. Over 300 of these disorders have been identified thus far, and the causative mutations lower immune defense against the attack of infections.

HIV is, of course, an example of a secondary (acquired) immunodeficiency disorder. FCM analysis of CD4 and other markers on lymphocytes in the peripheral blood is used to monitor the treatment of HIV patients, and a CD4 count <200 cells/mL together with a positive antibody test for HIV is used as a diagnostic for AIDS.1 Secondary immunodeficiencies can also be caused by e.g., substance abuse, malnutrition, other medical conditions, and certain medical treatments. FCM of a panel of markers can be used to confirm suspected cases.1In pregnancy, when a Rhesus blood group D-negative mother carries a D-positive fetus, fetal-maternal bleeding can sensitize the mother to the D-positive blood cells from the fetus and this can be fatal to subsequent D-positive newborns.11 FCM is used to measure the degree of fetal-maternal hemorrhage to determine the correct dose of prophylactics to be administered shortly after delivery.

In addition to oncology and immunology applications, FCM is also used to diagnose a variety of rare hematologic disorders12 as well as autoimmune/autoinflammatory disorders such as spondylarthritis (arthritis of the spine).13 Another area of research that is likely to give rise to increasing clinical applications in the future is that of platelet activity, which is important in many clinical conditions.1,14

Experts suggest that it may be possible to overcome this data analysis hurdle by applying machine learning approaches coupled with further standardization of FCM workflows.3,15 The most exciting applications of high content data revolve around the use of machine learning, in particular, deep learning, to extract relevant meaning from large data sets. Machine learning, coupled with big data, has the potential for driving diagnosis and treatment options tailored to the patients disease in a timely manner, says Dr. Parsons. In addition, Prof. Sadao Ota of RCAST at the University of Tokyo, Japan, points out, We still need to figure out how to design a workflow that convincingly validates diagnostic results, especially if the diagnosis employs the power of machine learning. Such developments are necessary before the rich information content of advanced FCM technology can be fully applied in the clinic.

In terms of other future advances in the field, Prof. Ota specifically makes mention of the potential of cell sorters combined with FCM.16 There are exciting and unique applications of sorters in fields such as cell therapy and regenerative medicine. Also, creating key applications of imaging cell sorters in pharmaceutical fields may accelerate global drug discovery. Dr. Doan concurs, Disease heterogeneity makes it hard to validate findings. Perhaps the use of flow cytometry with sorting capability can help such validation, where events-of-interest collected by flow cytometry can be validated with other downstream assays. Finally, as Dr. Doan notes, With multiple layers of data(types) incorporated altogether, there are now possibilities to do more with less, i.e., label-free sample measurement, which could lead to more direct, faster, and smarter diagnoses. Rare events (e.g., metastatic cancer cells) may soon be detected better than before.References1.Bakke A.C. Clinical Applications of Flow Cytometry. Laboratory Medicine. 2000; 31(2): 97104. doi: 10.1309/FC96-DDY4-2CRA-71FK.2.Herzenberg L.A., Parks D., Sahaf B., Perez O., Roederer M., Herzenberg L.A. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clinical Chemistry. 2002;48(10):181918273.Doan M., Vorobjev I., Rees P., Filby A., Wolkenhauer O., Goldfeld A.E., Lieberman J., Barteneva N., Carpenter A.E., Hennig H. Diagnostic potential of imaging flow cytometry. Trends in Biotechnology. 2018;36(7):649652. doi: 10.1016/j.tibtech.2017.12.008.4.Olsen L.R, Leipold M.D., Pedersen C.B., Maecker H.T. The anatomy of single cell mass cytometry data. Cytometry Part A. 2019;95(2):156172. doi: 10.1002/cyto.a.23621.5.Laerum O.D., Farsund T. Clinical application of flow cytometry: a review. Cytometry. 1981;2(1):113. doi: 10.1002/cyto.990020102.6.Li J., Wertheim G., Paessler M., Pillai V. Flow cytometry in pediatric hematopoietic malignancies. Clinics in Laboratory Medicine. 2017;37(4):879893. doi: 10.1016/j.cll.2017.07.009.7.Gupta S., Devidas M., Loh M.L., Raetz E.A., Chen S., Wang C., Brown P., Carroll A.J., Heerema N.A., Gastier-Foster J.M., Dunsmore K.P., Larsen E.C., Maloney K.W., Mattano L.A. Jr., Winter S.S., Winick N.J., Carroll W.L., Hunger S.P., Borowitz M.J., Wood B.L. Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Childrens Oncology Group (COG). Leukemia. 2018;32(6):13701379. doi: 10.1038/s41375-018-0039-7.8.Kobayashi H., Lei C., Wu Y., Huang C-J., Yasumoto A., Jona M., Li W., Wu Y., Yalikun Y., Jiang Y., Guo B., Sun C-W., Tanaka Y., Yamada M., Yatomi Y., Goda K. Intelligent whole-blood imaging flow cytometry for simple, rapid, and cost-effective drug-susceptibility testing of leukemia. Lab on a Chip. 2019;19(16):26882698. doi: 10.1039/c8lc01370e.9.Castegnaro S., Dragone P., Chieregato K., Alghisi A., Rodeghiero F., Astori G. Enumeration of residual white blood cells in leukoreduced blood products: Comparing flow cytometry with a portable microscopic cell counter. Transfusion and Apheresis Science. 2016;54(2):266270. doi: 10.1016/j.transci.2015.10.001.10.Abraham R.S., Aubert G. Flow cytometry, a versatile tool for diagnosis and monitoring of primary immunodeficiencies. Clinical and Vaccine Immunology. 2016;23(4):254271. doi: 10.1128/CVI.00001-16.11.Kim Y.A., Makar R.S. Detection of fetomaternal hemorrhage. American Journal of Hematology. 2012;87(4):417423. doi: 10.1002/ajh.22255.12.Bn M.C., Le Bris Y., Robillard N., Wuillme S., Fouassier M., Eveillard M. Flow cytometry in hematological nonmalignant disorders. International Journal of Laboratory Hematology. 2016;38(1):516. doi: 10.1111/ijlh.12438.13.Duan Z., Gui Y., Li C., Lin J., Gober H.J., Qin J., Li D., Wang L. The immune dysfunction in ankylosing spondylitis patients. Bioscience Trends. 2017;11(1):6976. doi: 10.5582/bst.2016.01171.14.Pasalic L. Assessment of platelet function in whole blood by flow cytometry. Methods in Molecular Biology. 2017;1646:349367. doi: 10.1007/978-1-4939-7196-1_27.15.Doan M., Carpenter A.E. Leveraging machine vision in cell-based diagnostics to do more with less. Nature Materials. 2019;18(5):414418. doi: 10.1038/s41563-019-0339-y.16.Ota S., Horisaki R., Kawamura Y., Ugawa M., Sato I., Hashimoto K., Kamesawa R., Setoyama K., Yamaguchi S., Fujiu K., Waki K., Noji H. Ghost cytometry. Science. 2018;360(6394):12461251. doi: 10.1126/science.aan0096.

See the rest here:
The Value and Versatility of Clinical Flow Cytometry - Technology Networks

Global Cell Harvesting Industry Research: Key Companies Profile with Sales, Revenue, Market Share, Price and Competitive Situation Analysis – Inquiry…

Cell harvesting usually for use in cancer or other treatment. Usually the cells are removed from the patients own bone marrow. Stem cells can be harvested from the blood or bone marrow. Umbilical cords have been saved as a future source of stem cells for the baby.

Access Report Details at: https://www.themarketreports.com/report/global-cell-harvesting-market-by-manufacturers-regions-type-and-application-forecast

Market share of global Cell Harvesting industry is dominate by companies like PerkinElmer (US), Brandel (US), TOMTEC (US), Cox Scientific (UK), Connectorate (Switzerland), Scinomix (US), ADSTEC (Japan), Sartorius, Terumo Corporation and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018).

With the help of 15 chapters spread over 100 pages this report describe Cell Harvesting Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Cell Harvesting, in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2019 to 2024 is provided in this research report. At last information about Cell Harvesting sales channel, distributors, traders, dealers, and research findings completes the global Cell Harvesting market research report.

Market Segment by Regions, regional analysis covers:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia, etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

Manual

Automated

Market Segment by Applications, can be divided into

Biopharmaceutical

Stem Cell Research

Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1496763

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Cell Harvesting Market Competitions, by Manufacturer

4 Global Cell Harvesting Market Analysis by Regions

5 North America Cell Harvesting by Countries

6 Europe Cell Harvesting by Countries

7 Asia-Pacific Cell Harvesting by Countries

8 South America Cell Harvesting by Countries

9 Middle East and Africa Cell Harvesting by Countries

10 Global Cell Harvesting Market Segment by Type

11 Global Cell Harvesting Market Segment by Application

12 Cell Harvesting Market Forecast (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1496763

More:
Global Cell Harvesting Industry Research: Key Companies Profile with Sales, Revenue, Market Share, Price and Competitive Situation Analysis - Inquiry...

Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment – The Market Journal

Advance Market Analytics released a comprehensive study of 200+ pages on Anti-Aging Products and Therapies market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are Allergan plc (Ireland), Ipsen (France), Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (China), Estee Lauder Companies Inc. (United States), Avon Products, Inc. (United Kingdom), Galderma S.A. (Switzerland), LG Life Sciences, Ltd. (South Korea), Bohus Biotech AB (Sweden), Imeik Technology Development Co Ltd (China), Merck & Co., Inc. (United States), Gaoxin Zhangtong Co. Ltd. (China)

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/36862-global-anti-aging-products-and-therapies-market

Due to rise in aging populations in several developed and developing countries, the anti-aging products and therapies market will grow robustly over the forecasted period. In addition to this, the rising number of medical tourism for cosmetic procedures, as well as technological advancement in the field of anti-aging will further escalate the demand for anti-aging treatments and ultimately anti-aging products. Moreover, the growing adoption of minimally invasive anti-aging treatments and introduction to non-invasive laser treatments will attract global population. However, some of the severe side effects for the skin treatments might stagnate the demand for anti-aging products and treatments. Aging relates to maturing or growing old in terms of endurance, agility, strength, basal metabolism, speed of reaction, hearing acuity and many others. In case of geriatric population, the skin drier & less elastic; bones are comparatively brittle, and the teeth are shed.

Market Segmentationby Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid), Application (Anti-Pigmentation Therapy, Anti-Cellulite Treatment, Anti-Wrinkle Treatment, Acne Management, Scar Treatment, Others), Active Ingredients (Retinol, Peptides, Argirelline), Distribution Channel (Dermatology Clinics, Hospitals, Pharmacies, Drug Stores, Rejuvenation Centers, Others.), Service (BOTOX, Proteomics, Gene Therapy, HRT, Dermal Fillers, Plastic Surgery)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/36862-global-anti-aging-products-and-therapies-market

Whats Trending in Market: Introduction to Highly Advanced Skin Treatments such as Neuromodulators For Tauter Skin

Adoption of New Age Fillers like Hyaluronic acid and Calcium Hydroxyapatite Fillers

Growth Drivers: Increasing Geriatric Population across the Globe will boost the Demand

Rising Health Consciousness Among Consumers

Restraints: Significant Side-Effects of the Dermal Treatments for instance; Chemicals Available in Cosmetic Products are Found in Biopsies from Breast Tumors

Excessive Use might Disturb the Hormone Function of Consumer

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/36862-global-anti-aging-products-and-therapies-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

On Special Request we do offer a dedicated and focus report on regional or by country level scope.

GET FULL COPY OF United States Anti-Aging Products and Therapies market study @ USD 2000

And, Asia-Pacific Anti-Aging Products and Therapies market study @ USD 2500

Major Highlights of TOC:

Chapter One: Market Overview

Scope/Objective of the Study

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD400

Market Drivers, Market Challenges, Market Trends

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain Analysis, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Market Development Scenario

Chapter Five and Seven: Global Anti-Aging Products and Therapies, by Market Segmentation and Region (value, volume**) (2013-2024) USD2400

Global Anti-Aging Products and Therapies

By Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid)

By Application (Anti-Pigmentation Therapy, Anti-Cellulite Treatment, Anti-Wrinkle Treatment, Acne Management, Scar Treatment, Others)

By Active Ingredients (Retinol, Peptides, Argirelline)

By Distribution Channel (Dermatology Clinics, Hospitals, Pharmacies, Drug Stores, Rejuvenation Centers, Others.)

By Service (BOTOX, Proteomics, Gene Therapy, HRT, Dermal Fillers, Plastic Surgery)

Global Anti-Aging Products and Therapies Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Anti-Aging Products and Therapies Manufacturers/Players Analysis USD1200

Competitive Landscape (Direct & Indirect Competitors), Market Share Analysis, Peer Group Analysis (2018), BCG Matrix, Company Profile, Downstream Buyers & Upstream Suppliers

..

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicable* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=36862

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@advancemarketanalytics.comPh: +1 (206) 317 1218

View original post here:
Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment - The Market Journal

Gary Pesselt: Vitality Healthcare is it worth the cost? – The Union of Grass Valley

Another seminar is again advertised in The Union. I first thought it might help my wife with neuropathy until I did some extensive research.

First off, Medicare does not cover stem cell injections. Bone marrow stem cell injections range from $2,000 to $5,000 or more. Read Consumer Research report at: https://www.consumerreports.org/medical-treatments-procedures/trouble-with-stem-cell-therapy.

Stem cell treatments are widely accepted only for two broad medical indications: to help treat a handful of blood disorders including leukemia and some forms of anemia and in some cases to help burn victims. Ask questions. Any doctor who offers stem cell therapy should be able to explain where the cells will come from, what will be done to them before theyre injected into your body, and how, exactly, they will resolve your illness or injury. He or she should also be able to offer you proof of safety and efficacy, even for experimental treatments. Dont rely on patient testimonials.

Stem cells survive much longer than ordinary cells, increasing the chance that they might accumulate genetic mutations. It might take only a few mutations for one cell to lose control over its self-renewal and growth and become the source of cancer. Please do your own research.

Gary Pesselt

Grass Valley

Follow this link:
Gary Pesselt: Vitality Healthcare is it worth the cost? - The Union of Grass Valley

Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research – GuruFocus.com

Stem cells can repair and self-renewal damaged cells and can thus be used to treat various medical conditions. These cells are stored as they have the potential for usage in the treatment of any medical conditions that the person can further from in the future. The collected stem cells are cryopreserved and stored for decades, which can be later used to treat large number of chronic diseases such as leukemia, thalassemia, and diabetes.

The global stem cell banking market was valued at $1,986 million in 2016, and is estimated to reach $6,956 million by 2023, registering a CAGR of 19.5% from 2017 to 2023. North America is the highest contributor in the stem cell banking market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Click Here To Access The Sample Report @ https://www.alliedmarketresearch.com/request-sample/4614

Rise in number of births occurring globally, increase in R&D activities in regards with applications of stem cells, and surge in prevalence of fatal chronic diseases drive the growth of the market. The growth in GDP & disposable income globally is projected to help increase the number of stem cell units stored, which in turn boosts the market growth. However, legal and ethical issues related to stem cell collections and lack of acceptance and awareness in the developing regions are projected to hinder the market growth.

Among the cell type, the umbilical cord stem cell segment dominates the market, as these stem cells can be used to treat almost 80 diseases and the extraction process is easy and does to harm the newborn in any way. However, the adult stem cell segment is expected to register the highest growth rate during the forecast period.

Depending on bank type, the private stem cell banking is the dominant segment in the stem cell banking market. Although the number of public banks are more than private banks, the revenue generated by private stem cell banks are more, which contributes toward the growth of the market.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4614

Key Findings of the Stem Cell Banking Market:

Used stem cells is projected to grow at the highest rate among the utilization segment during the analysis period.

North America dominated global stem cell banking market in 2016, and is projected to continue its dominance in future.

China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.

Storage service segment was the largest contributor among the service type segments in 2016.

The private stem cell bank generated the highest revenue, and is expected to continue its dominance in future.

In 2016, North America was the major revenue contributor, owing to increase in awareness toward the benefits of storing stem cell and favorable regulatory scenario. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, due to high birth rate in populace countries such as India and China.

The key players operating in the global stem cell banking market include Cord Blood Registry, ViaCord, Cryo-Cell, China Cord Blood Corporation, Cryo-Save, New York Cord Blood Program, CordVida, Americord, CryoHoldco, and Vita34. Other prominent players in the value chain include Caladrius Biosciences, Cryoviva, Smart Cells International Ltd., Stemade Biotech, Cytori Therapeutics, Cellular Dynamics International, PerkinElmer, and Reelabs.

Obtain Report Details: https://www.alliedmarketresearch.com/stem-cell-banking-market

About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free: +1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975[emailprotected]https://www.linkedin.com/company/allied-market-researchFollow Us on Twitter: https://twitter.com/marketresearcht

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

The rest is here:
Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research - GuruFocus.com

Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – Weekly Spy

Stem Cell Therapy Market is expected to reach 202.77 billion by 2026 from 12.25 billion in 2017 at CAGR of 42.02%.(Detailed analysis of the market CAGR is provided in the report) stands for use of stem cells to treat or prevent disease or condition.Stem Cell Therapy Market

Bone marrow transplant and some therapies derived from umbilical cord blood are mainly used in stem cell therapy. Advancement, in order to establish new sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions, are increased in recent years. Stem Cell Therapy Market Researchers are making efforts to discover novel methods to create human stem cells. This will increase the demand as well as supply for stem cell production and potential investigation in disease management. Increasing investment & research grants for developing safe and effective stem cell therapy products, the growing patient base for target diseases, concentrated product pipelines, increasing approval of the new clinical trials, rapid technological advancement in genomics, and the rising awareness about the stem cell are expected to drive the growth of the Stem Cell Therapy solutions market during the forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/522

However, improper infrastructure, insufficient storage systems, nascent technology in underdeveloped economies, Ethical issues related to an embryonic stem cell, low patient acceptance rate, Difficulty in the preservation of stem cell are expected to restrain the market growth. North America is expected to be the largest growing region by 2026; the reason behind that is extensive funding by Government. However, Emerging countries like India, china, Korea have low growth rate as compared to Developed regions in 2017 but increase in awareness about stem cell therapy will lead the Asia Pacific to generate a significant level of revenue by 2026.Key Highlights of Stem Cell Therapy Market report

Detailed quantitative analysis of the current and future trends from 2017 to 2026, which helps to identify the prevailing market opportunities.Comprehensive analysis of factors instrumental in changing the market scenario, rising prospective opportunities, market shares, core competencies in terms of market development, growth strategies and identification of key companies that can influence this market on a global and regional scale.Assessment of Market definition along with the identification of key drivers, restraints opportunities and challenges for this market during the forecast period.Complete analysis of micro-markets with respect to individual growth trends, prospects, and contributions to the overall Stem Cell Therapy Solutions market.Stem Cell Therapy market analysis and comprehensive segmentation with respect to the Application, End users, Treatment, and geography to assist in strategic business planning.Stem Cell Therapy market analysis and forecast for five major geographies-North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions.For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a global market value for the stem cell therapy market.

Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Key Target Audience:

Stem Cell Associations and OrganizationsGovernment Research Boards and OrganizationsResearch and consulting firmsStem Cell Therapy Market InvestorsHealthcare Service Providers (including Hospitals and Diagnostic Centers)Stem Cell Therapeutic Product Manufacturing OrganizationsResearch LabsClinical research organizations (CROs)Stem Cell Therapy Marketing PlayersPharmaceutical Product Manufacturing Companies

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/522

Scope of the Stem Cell Therapy Market Report:

Stem Cell Therapy market research report categorizes the Stem Cell Therapy market based on Application, End users, Treatment, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Stem Cell Therapy market with key developments in companies and market trends.Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:HospitalsAmbulatory Surgical CentersStem Cell Therapy Market, By Application:OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Therapy Market Competition, by Players

Chapter Four: Global Stem Cell Therapy Market Size by Regions

Chapter Five: North America Stem Cell Therapy Revenue by Countries

Chapter Six: Europe Stem Cell Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Therapy Revenue by Countries

Chapter Eight: South America Stem Cell Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Therapy by Countries

Chapter Ten: Global Stem Cell Therapy Market Segment by Type

Chapter Eleven: Global Stem Cell Therapy Market Segment by Application

Chapter Twelve: Global Stem Cell Therapy Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Stem Cell Therapy Market Report at: https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See more here:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Weekly Spy

Analysis of Regenerative Medicine Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to…

The Regenerative Medicine Market research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend.Regenerative Medicine market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Regenerative Medicine market report also offers market competitors that includes detailed company profiles along with company product specifications.

Reasons for Buying Regenerative Medicine Market Report:

For More Information or Query or Customization Before Buying, Visit athttps://www.industryresearch.co/enquiry/pre-order-enquiry/14244620

Key Market Trends:

Dermatology is the Segment by Application that is Expected to be the Largest During the Forecast Period

Dermatology is estimated to have the largest share in revenue generation, and this high contribution is attributive to the presence of easy grafting techniques for dermatological wounds and diseases. Skin, being an organ with great cell replication characteristics, provides various types of stem cells from its different layers. Therefore, there are a broad range of products present, from patches to cure small injuries to matrix and grafts for chronic wounds and burns. Thus, the segment is expected to continue to dominate the market through to the forecast period.

The increasing number of accidents and bone defects is also expected to drive the regenerative medicine market. There are also several research studies that are being conducted on tissue engineering for the development of bone graft substitutes, with the help of regenerative medicine. So, with the new advances in bone graft, the market is expected to grow over the forecast period.

North America Holds the Largest Share and is Expected to Follow the Same Trend Over the Forecast Period

North America is estimated to have the largest share, in terms of revenue, owing to the presence of major players and rapid advances in technology, along with high investments in stem cell and oncology research. There is also an increasing prevalence of diseases, such as cancer and diabetes, which can now be cured by various stem cell therapies. Additionally, the awareness regarding the available stem cell procedures and therapies among people is rising, which in turn, is increasing the demand for the overall market.

The Research Document Will Answer Following Questions Such as:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14244620

Detailed TOC of Regenerative Medicine Market Report 2019-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Adoption of Stem Cell Technology4.2.2 Technological Advancements in Regenerative Medicine4.3 Market Restraints4.3.1 Regulatory and Ethical Issues4.3.2 High Cost of Treatments4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Type of Technology5.1.1 Stem Cell Therapy5.1.2 Biomaterial5.1.3 Tissue Engineering5.1.4 Other Types of Technologies5.2 By Application5.2.1 Bone Graft Substitutes5.2.2 Osteoarticular Diseases5.2.3 Dermatology5.2.4 Cardiovascular5.2.5 Central Nervous System5.2.6 Other Applications5.3 Geography5.3.1 North America5.3.1.1 United States5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 Germany5.3.2.2 United Kingdom5.3.2.3 France5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Allergan6.1.2 Osiris Therapeutics6.1.3 Integra Lifesciences6.1.4 Cook Biotech Incorporated6.1.5 Organogenesis Inc.6.1.6 Baxter6.1.7 Medtronic6.1.8 Thermo Fisher Scientific6.1.9 Sigma-Aldrich Co.6.1.10 Becton Dickinson and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Home Bedding Market 2019-2024 | Size, Share, Future Demands, Development Strategy, Sales-Revenue, Growth Factors, Industry Updates and Key Players Analysis Available at Industry Research Biz

Global Cellulose Powder Market 2019: Industry Size & Share, Business Strategies, Growth Analysis, Segments, Revenue, Key Manufacturers and 2024 Forecast Research Report

Dermal Fillers for Cosmetic Surgery Market 2019 Global Industry Scope, Competition Strategies, Gross Margin Analysis by Size & Share, and Forecast to 2023

Hemp Market Report 2018 Analysis by Market Players, Size, Share, Growth Rate, Opportunities, Drivers, and Risk Factor Forecast to 2023

Go here to see the original:
Analysis of Regenerative Medicine Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to...

Dee Ford on Monday night showdown: The blood is in the water with these games – AL.com

Defensive end Dee Ford has become a fixture on the San Francisco 49ers injury report. Every week, hes listed. But every game, hes played.

As Ford deals with knee tendinitis and irritation of the quadriceps muscle, the 49ers have picked his spots on the field. By using him as a situational pass-rusher, San Francisco has been able to get 5.5 sacks and two forced fumbles from Ford while using the former Auburn standout on 39 percent of the 49ers defense snaps.

Youre going to have nicks and bruises, Ford said during an appearance on KNBR-FM in San Francisco. Well, its not bruised; I wish it was. Ive been in situations where Ive had to handle worser things, so my maintenance, you have to keep it strong. Weve got a great strength staff, a great trainer, so were on a great plan each week, so I got to put in a little extra work, but Im the man for the job and Ill be ready to go. If I can play, Im going to play.

Ford recorded 13 sacks and led the NFL with seven forced fumbles for the Kansas City Chiefs in 2018.

The 49ers obtained Ford in March, sending a second-round selection in the 2020 NFL Draft to Kansas City after the Chiefs had placed their franchise tag on the pass-rusher to keep him off the free-agent market.

San Francisco signed Ford to a five-year, $85.5 million contract and addressed his left-knee condition by having Ford get platelet-rich plasma injections while missing about four weeks of the training camp/preseason period.

I love my teammates, and thats a real thing, Ford said of his move to San Francisco. I know a lot of teammates say that, but weve been building chemistry since OTAs, so where were at right now as team is special, special, especially upfront.

San Francisco is the NFL's only undefeated team after winning four games last season. The 49ers defense has given up the fewest total yards and the fewest passing yards in the NFL in 2019.

A key component to San Francisco's defensive success has been its pass rush. The 49ers rank fourth in the NFL with 30 sacks.

All four guys have to work together, and we really put in the effort to work together, Ford said of the 49ers defensive line. "You can look around the league. Theres a lot of D-lines that its just not the same result and some play as individuals. Im not throwing shade, but we really work together. And thats a lot of credit to Kris Kocurek, our (defensive-line) coach. He really helped us glue the thing together and play together. We do not play as individuals.

"As you can see, you never know who's going to have -- that's the crazy part about these games: You don't know who's going to have the hot hand upfront. You never know. But we all play together. Nobody's trying to make the big play. Everybody wants to get sacks, of course, but nobody's coming out of what we do to try to make a play, and that's the special thing about this front."

Rookie defensive end Nick Bosa leads the 49ers with seven sacks, but 10 San Francisco players have recorded sacks in 2019.

I think theyre the top group in the whole league and just their style of play, the way theyre coaching them, Seattle Seahawks coach Pete Carroll said. I think Bosa adding to those guys has been a big addition. Dee Ford has really fit in well on third-down situations. Theyre flying and theyre about as good as you can hope to be now. Theyre really getting it done.

The 49ers will square off against the Seahawks in an NFC West rivalry game at 7:15 p.m. CST Monday at Levi's Stadium in Santa Clara, California. ESPN will televise the game.

Seattle will enter the final game of Week 10 of the NFL's 2019 season with a 7-2 record. San Francisco has an 8-0 mark after beating the Arizona Cardinals 28-25 on Oct. 31 in the first game of Week 9.

I felt it as soon as the Arizona game was over: Its Seattle week, Ford said. Its real, man. Its a real thing. The blood is in the water with these games. You never know what youre going to get, so both teams have to gear up.

Ford traces his current knee problem to a 2013 injury, when he tore the medial collateral ligament in his left knee about two weeks before his senior season at Auburn kicked off. Ford missed the first two games, but he returned to register 10.5 sacks as the Tigers won the SEC championship and reached the BCS national-championship game.

Back surgery for a herniated disk in 2011 had caused Ford to take a medical redshirt after his first two seasons at Auburn. The former St. Clair County High School star also required back surgery again that cost him 10 games during the 2017 NFL season.

Mark Inabinett is a sports reporter for Alabama Media Group. Follow him on Twitter at @AMarkG1.

More NFL coverage:

Check out Rashaan Evans 53-yard scoop-and-score for his first NFL touchdown

Sunday will feel a little weird for Steelers Mark Barron

Green Bay feeling like Auburn to Montravius Adams

Josh Jacobs TD run lifts Raiders to Thursday night win

Fred Biletnikoff: Ken Stabler should have been MVP of Super Bowl XI

Jermaine Whitehead: That was totally out of character for me

Carolina Panthers put Cam Newton on injured reserve

Joe Namath, Bo Jackson included among NFLs greatest game changers

Continued here:
Dee Ford on Monday night showdown: The blood is in the water with these games - AL.com

Ixazomib Extends Survival in Multiple Myeloma for Patients Not Treated With Stem Cell Transplantation – Pharmacy Times

Ixazomib Extends Survival in Multiple Myeloma for Patients Not Treated With Stem Cell Transplantation

The phase 3 TOURMALINE-MM4 study evaluated single-agent oral ixazomib as first-line maintenance therapy versus placebo in 706 adult patients diagnosed with MM not treated with stem cell transplantation, who have completed 6 to 12 months of initial therapy and achieved a partial response or better.

New data from the study have demonstrated statistically significant improvement in PFS, meeting the primary endpoint of the trial, Takeda announced. According to the press release, this is the first industry-sponsored phase 3 trial to investigate the concept of switch maintenance, the use of medications not included in initial induction therapy, in this setting.

First approved by the FDA in November 2015, ixazomib is an oral proteasome inhibitor being studied across several MM treatment settings, according to Takeda. It is currently indicated in combination with lenalidomide and dexamethasone for the treatment of patients with MM who have received at least 1 prior therapy.

The TOURMALINE clinical development program includes ongoing clinical trials involving ixazomib in MM:

Reference

Phase 3 Trial Ninlaro (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation [news release]. Takedas website. https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/. Accessed November 7, 2019.

Read more here:
Ixazomib Extends Survival in Multiple Myeloma for Patients Not Treated With Stem Cell Transplantation - Pharmacy Times